Corey A. Collins Promoted to CEO of Tekton Research
AUSTIN, Texas — Tekton Research, a prominent player in multi-site clinical trials, is thrilled to announce the recent promotion of Corey A. Collins to Chief Executive Officer (CEO). This strategic move is set to drive the company's next chapter of growth and innovation.
Collins' Professional Journey and Contribution
Collins has been part of the Tekton family since December 2023, initially coming on board as Chief Financial Officer. His substantial experience of over 20 years in financial and operational leadership spans across critical sectors, including pharmaceuticals and manufacturing. Before joining Tekton, he served in significant roles at American Expediting, Dicalite Management Group, and PCI Pharma Services, where he successfully shaped financial strategies for sustained success.
Pivotal Leadership Transition
In January 2025, Collins transitioned to President following the departure of the founding CEO, Kip McKenzie. Under his direction, Tekton has sustained a vigorous growth trajectory with an enhanced focus on two primary therapeutic areas: Central Nervous System (CNS) and Cardiometabolics. This shift has allowed the organization to improve operational excellence and refine its commercial strategies significantly.
Strategic Developments Under Collins' Leadership
Since stepping into the President's position and now as CEO, Collins has focused on strengthening Tekton's operational framework, achieving a harmonious integration of technologies, and assembling a dynamic executive team. Notably, in 2025 alone, Tekton expanded by adding seven new research sites, underscoring its commitment to furthering research capabilities to benefit both patients and partners.
Endorsements from Board Members
Wendel D. Barr, Tekton's Chairman of the Board, expressed high regard for Collins' leadership capabilities, stating, "Corey's leadership has already played a pivotal role in Tekton's growth. His ability to pair financial acumen with strategic vision has positioned Tekton to build on our strong foundation and accelerate our mission in clinical research." This endorsement highlights the confidence and expectations placed upon Collins as he steps into his new role.
Commitment to Clinical Quality and Operational Rigor
Christopher W. Kersey, M.D., M.B.A., a Founding Managing Partner of Havencrest Capital Management, also conveyed his congratulations, emphasizing, "Corey's uncompromising focus on clinical quality is complemented by his commitment to operational rigor and his successful recruitment of the clinical trial industry's best professionals." Such recognition speaks volumes about Collins' influence and potential to steer Tekton towards greater achievements.
Collins' Vision for Tekton
Reflecting on his promotion, Collins expressed deep gratitude, stating, "It's an honor to step into the role of CEO and continue building on Tekton's legacy. I'm proud of the progress we've made this year, and I'm even more excited about what's ahead as we grow our footprint, invest in technology and remain focused on delivering high-quality research in CNS and Cardiometabolics." His vision shows a commitment to both growth and excellence as Tekton enters this new phase.
Recent Expansion Initiatives
This announcement aligns with Tekton's recent strategic expansions, which have resulted in three new research sites, the onboarding of five new investigators, and the introduction of a leading voice in CNS research. Each step emphasizes Tekton's dedication to precision, data integrity, operational quality, and patient-centered standards.
About Tekton Research
Founded in 2006, Tekton Research is a multi-site clinical trial company dedicated to conducting Phase 1-4 trials across various fields, including CNS, cardiometabolic, general medicine, and infectious diseases. With a team of nationally recognized experts, the company is committed to delivering scientific rigor and operational excellence. Tekton collaborates with sponsors, CROs, and biopharma partners to fast-track the development of therapies while maintaining a patient-focused approach.
About Havencrest Capital Management
Headquartered in Dallas, Havencrest Capital Management specializes in healthcare-focused private equity funds, managing over $700 million in assets. The firm boasts a team of seasoned investment professionals, operating partners, and senior advisors, including leading healthcare entrepreneurs and policy experts. Their knowledge and expertise have propelled many founder-owned healthcare companies to innovative heights.
Frequently Asked Questions
Who is Corey A. Collins?
Corey A. Collins is the newly appointed CEO of Tekton Research, previously serving as the Chief Financial Officer.
What are Collins' key areas of focus at Tekton?
Collins aims to enhance operational excellence and focus on CNS and Cardiometabolics therapeutic areas.
How many research sites has Tekton expanded in 2025?
Tekton has expanded by adding seven new research sites in 2025, showcasing its commitment to growth.
What is Tekton Research known for?
Tekton Research specializes in multi-site clinical trials and is recognized for scientific rigor and operational excellence.
What initiatives has Tekton taken recently?
Recently, Tekton has expanded its workforce with new investigators and leaders in CNS research, underlining its commitment to quality and excellence.
